AL
CELG

Aspiriant LLC’s Celgene Corp CELG Stock Holding History

Aspiriant LLC’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,345
Closed -$266K – 266
2018
Q2 		$266K Sell
3,345
-1,211
-27% -$101K 0.02% 216
2018
Q1 		$406K Buy
+4,556
New +$437K 0.04% 162
2017
Q4 		– Sell
-9,014
Closed -$1.31M – 204
2017
Q3 		$1.31M Sell
9,014
-1,490
-14% -$203K 0.11% 93
2017
Q2 		$1.36M Sell
10,504
-1,744
-14% -$214K 0.12% 96
2017
Q1 		$1.52M Buy
12,248
+395
+3% +$47.3K 0.13% 96
2016
Q4 		$1.37M Sell
11,853
-119
-1% -$13.3K 0.12% 90
2016
Q3 		$1.25M Buy
+11,972
New +$1.3M 0.12% 93

Other funds holding CELG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aspiriant LLC's CELG Position: Q3 2018 in Review

Aspiriant LLC sold out of Celgene Corp (CELG) in Q3 2018, closing a stake of 3,345 shares — an estimated $266K sold.

Aspiriant LLC first reported a position in CELG in Q3 2016 and held it in 7 quarters. The position peaked at $1.52M in Q1 2017. 1,364 funds tracked by Wall St. Rank hold CELG as of Q3 2018.

  • Aspiriant LLC reported no remaining Celgene Corp position as of Q3 2018 after selling out during the quarter.
  • Aspiriant LLC sold 3,345 Celgene Corp shares in Q3 2018, an estimated $266K.
  • Aspiriant LLC first reported a position in Celgene Corp in Q3 2016 and held it in 7 quarters.
  • Aspiriant LLC's Celgene Corp position peaked at $1.52M in Q1 2017.
  • 1,364 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2018.

Based on Aspiriant LLC's 13F filing for Q3 2018, filed 26 Oct 2018.